home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

Property-Based Drug Design

  February 11, 2014  
Westin Boston Waterfront, Boston, MA, USA
May 22-23, 2014

One of the most challenging aspects of drug discovery remaining is the identification of new molecular entities (NMEs) with the desirable physicochemical properties and absorption, distribution, metabolism, and excretion (ADME) profiles that can be formulated into safe and efficacious drug products. The third annual Property-Based Drug Design conference will bring together leading experts from industry and academia to discuss advanced tools and technologies being used for better understanding of physicochemical and bio-physical properties and how the new understanding is applied to the drug discovery processes and pharmaceutical development.

This annual conference will feature informative, high-quality case studies and successful strategies to overcome the problems you are facing in the rapidly changing drug discovery landscape. We invite you to present a talk, a poster, or to attend to learn from and network with the leading experts from around the world.
Organized by: Cambridge Healthtech Institute (CHI)
Invited Speakers:
  • Nicholas Meanwell, Ph.D., Executive Director, Department of Chemistry, Research and Development, Bristol-Myers Squibb Co.
  • W. Patrick Walters, Ph.D., Principal Research Fellow, Group Head, Computational Sciences, Vertex Pharmaceuticals, Inc.
  • Terry Richard Stouch, Ph.D., President, Science for Solutions, LLC
  • Phil Cox, Ph.D., Principal Research Scientist, Discovery Chemistry and Technology, Global Pharmaceutical R&D, Abbvie, Inc.
  • Li Di, Ph.D., Associate Research Fellow, Global Research and Development, Pfizer, Inc.
  • Michael A. Walker, Ph.D., Senior Principal Scientist, Department of Chemistry, Research and Development, Bristol-Myers Squibb Co.
  • Sarah L. Price, Ph.D., Professor of Physical Chemistry, Department of Chemistry, University College London
  • Patrick R. Connelly, Ph.D., Principal Scientific Fellow, Vertex Pharmaceuticals, Inc.
  • Harvey Lieberman, Ph.D., Senior Manager, Analytical Research & Development, Sanofi
  • Rebecca Nofsinger, Ph.D., Senior Research Pharmacist, Biopharmaceutics Group, Merck & Co., Inc
  • Steven LaPlante, Ph.D., Adjunct Professor, Institut National de la Recherche Scientifique (INRS) University; Founder & CEO, NMX Research & Solutions
  • Jan Wahlstrom, Ph.D., Director, Pharmacokinetics & Drug Metabolism, Amgen, Inc.
  • Darren McKerrecher, Ph.D., Associate Director, Medicinal Chemistry, Oncology iMED, AstraZeneca
  • Alfin D.N. Vaz, Associate Research Fellow, Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc.
  • Peter Fan, Ph.D., Scientist, DMPK, Genentech, Inc.
  • Arijit Chakravarty, Ph.D., Senior Scientist II, Modeling and Simulation, DMPK, Takeda Pharmaceuticals
Deadline for Abstracts: ---
Registration: Register now
E-mail: kwaterman@healthtech.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.